Status:
TERMINATED
Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer
Lead Sponsor:
Sudeep Gupta
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-70 years
Phase:
PHASE3
Brief Summary
One of the basic principles of cancer chemotherapy is that these drugs act exclusively or mainly on cells in cycle. Estrogens have been shown to increase the fraction of breast cancer cells in cycle. ...
Detailed Description
Results from a recent clinical study (1) show that tamoxifen administered concurrently with chemotherapy reduces the efficacy of the latter in patients with estrogen and/or progesterone receptor posit...
Eligibility Criteria
Inclusion
- 1\. Patients with histological or cytologic proof of breast cancer. 2. Patients with operable breast cancer. 3. Patients who are candidates for adjuvant chemotherapy according to the standard policy. 4. Patients who have no contraindication to anthracycline based chemotherapy. 5. Patients who give informed consent to participate in the study. 6. Patients who can be followed up and can take all cycles of chemotherapy at the participating institution. 7. Patients should not have a known second cancer, present or past.
Exclusion
- \-
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2012
Estimated Enrollment :
273 Patients enrolled
Trial Details
Trial ID
NCT00193726
Start Date
July 1 2005
End Date
March 30 2012
Last Update
September 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tata Memorial Hospital
Mumbai, Maharashtra, India, 400012